Josh Price

HIV: handling a killer condition

The first AIDS-related deaths began to surface almost 40 years ago in 1981. At that time, we had no effective medication and AIDS was a certain death sentence. At its peak, the AIDS crisis was killing 2 million people each year – people from all corners of society and across the...

Read more

Lowering the bar to purity claims

Every so often, the European Patent Office issues a decision on a case which has important consequences for other patent applicants. The recent decision T1085/13 (discussed in greater detail here) has implications for how purity claims are assessed at the EPO and may be seen as patentee-friendly, particularly for the...

Read more

The (little-known) route to patent revocation

All too frequently, a business discovers a competitor’s patent lurking in the wings, standing in the way of a new project or commercial product. However a very small percentage of those businesses know that patent revocation actions before the UK Intellectual Property Office can play a fundamental part in securing...

Read more

T1085/13: A crystal-clear test for purity

This recent decision from an EPO Board of Appeal is a rather satisfying development in how patentability (especially novelty) of purity claims is assessed at the EPO. This case may be seen as patentee-friendly, particularly for the pharmaceutical sector, as it likely extends protection for APIs. It will become especially...

Read more

Patent licensing trends in the UK pharmaceutical sector

2018 was billed by some in the industry as the year of pharma M&As. However, as of September, we still haven’t seen the acquisition values that were expected following a rather barren 2017. What we have seen are record high patent licensing deals. If your company is built on a...

Read more